title: Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
authors.forename: A A N
authors.initials: AA
authors.lastname: Giagounidis
authors.forename: A
authors.initials: A
authors.lastname: Kulasekararaj
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: R
authors.initials: R
authors.lastname: Radkowski
authors.forename: S
authors.initials: S
authors.lastname: Haase
authors.forename: P
authors.initials: P
authors.lastname: Petersen
authors.forename: G
authors.initials: G
authors.lastname: Göhring
authors.forename: G
authors.initials: G
authors.lastname: Büsche
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: G J
authors.initials: GJ
authors.lastname: Mufti
authors.forename: U
authors.initials: U
authors.lastname: Platzbecker
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001803:Blood Transfusion; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide